I am a Transplant Hepatologist and Clinical Professor of Medicine at UCSF. I am the Director of our Liver Cancer Multidisciplinary Program as well as the Medical Director of our Live Donor Liver Transplantation program. My research focus is primarily on selection criteria and liver transplant outcomes for patients with HCC including with respect to down-staging, incorporation of biomarkers, and improving transplant access.

Dr. Taner is a Professor of Surgery and Consultant in Immunology at Mayo Clinic, Rochester. He is the Chair of the Division of Transplantation Surgery at the same institution. His clinical practice involves liver transplantation, living donor hepatectomies and nephrectomies. His research focuses on liver transplant immunobiology, investigating interactions between liver allografts and host immune responses. He is the current co-Editor-in-Chief of Liver Transplantation.

Dr. Cárdenas is a Staff Member and Consultant of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and Accredited Professor of Medicine (Catalan Agency for Quality Assessment) with the University of Barcelona. He pursued his Residency and Fellowship in Internal Medicine, Gastroenterology, Hepatology at Boston University and Harvard Medical School at Beth Israel Deaconess Medical Center in Boston. Dr. Cardenas is Board Certified in Internal Medicine, Gastroenterology and Hepatology by the American Board of Internal Medicine.

Jose Debes MD PhD is a Professor in Medicine at the University of Minnesota in Minneapolis. His work centers on mechanisms of hepatitis-related liver cancer as well as awareness on risk factors for hepatitis B and liver cancer. He founded and leads two research networks in Latin America and in Africa

Dr. Hoshida is Professor of Internal Medicine at University of Texas Southwestern Medical Center. He is a hepatologist and physician scientist with expertise in translational research in liver cirrhosis and cancer with a specific focus on risk prediction, disease classification, and chemoprevention/therapeutic discovery.

Natalie J. Torok is a physician-scientist at Stanford University and the VA Palo Alto. The Torok lab's primary research interests are in the pathomechanisms of liver fibrosis and matrix remodeling and exploring translational aspects to prevent liver disease progression. Metabolic dysfunction associated steatohepatitis (MASH) is becoming the leading cause of chronic liver disease and liver cancer, and her lab is interested in deciphering how dynamic changes in the liver matrix accelerate this process in certain conditions such as type 2 diabetes.

Dr. Malhi is a consultant in the Division of Gastroenterology and Hepatology with a joint appointment in Physiology and a Professor of Medicine and Physiology at Mayo Clinic, Rochester, MN. She currently serves as the Vice Chair for the division of Gastroenterology and Hepatology. Dr. Malhi's laboratory studies lipotoxic endoplasmic reticulum stress, with particular research interest in mechanisms of liver injury and inflammation in nonalcoholic steatohepatitis pathogenesis.

Dr. Ibrahim is a Professor of Pediatrics and Physiology; she is a pediatric transplant hepatologist and a physician scientist. Samar is the Principal Investigator of the NIH-funded lipotoxicity and liver inflammation laboratory at Mayo Clinic. She studies mechanisms of liver injury and inflammation in metabolic dysfunction associated steatohepatitis (MASH) with the goal to identify novel biomarkers and mechanism-based therapeutic targets.

BC Sharma
Director Professor
Department of Gastroenterology and Hepatology
GIPMER, New Delhi
India
Research Fields
- Hepatic EncephalopathyY
- Portal Hypertension
Publications: 260 ( in leading journals like NEJM, Gastroenterology, Hepatology, J Hepatol and Gut)
- President APASL 2017-18
- President INASL 2026-27
- Asst Editor Hepatol International
- Member of National and International Journals Editorial Board
More than 100 National and International Fellowships and Awards

Dr. Patricia Bloom is an Assistant Professor and transplant hepatologist at the Mayo Clinic. She performs clinical and translational research to improve outcomes in decompensated cirrhosis, especially for hepatic encephalopathy. Her goals are to create and test innovative microbiome therapies to treat hepatic encephalopathy. She is also developing innovative technology solutions for the management of decompensated cirrhosis. She serves as an Associate Editor for Hepatology Communications and is Chair Elect of the Communications and Technology Committee of AASLD.